ArticleMarine drugs2020
Antimalarial Peptide and Polyketide Natural Products from the Fijian Marine Cyanobacterium
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Marine microbiomes and their expanding role in biotechnological potential: a systematic review.Archives of microbiology · 2026Pooled it
- Unveiling the cytotoxicity of Red SeaPharmaceutical biology · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- Review
- A Review on Synthetic Thiazole Derivatives as an Antimalarial Agent.Current drug discovery technologies · 2024Review
- Review
- An Overview on Antimalarial Peptides: Natural Sources, Synthetic Methodology and Biological Properties.Molecules (Basel, Switzerland) · 2023Review
- A Review of the Antimicrobial Properties of Cyanobacterial Natural Products.Molecules (Basel, Switzerland) · 2023Review
- ABiology · 2023Article
- Review of Marine Cyanobacteria and the Aspects Related to Their Roles: Chemical, Biological Properties, Nitrogen Fixation and Climate Change.Marine drugs · 2023Review
- Article
- Cyanobacteria: A Promising Source of Antifungal Metabolites.Marine drugs · 2023Review
- Cryptic Chemical Variation in a Marine Red Alga as Revealed by Nontargeted Metabolomics.ACS omega · 2023Article
- Lead/Drug Discovery from Natural Resources.Molecules (Basel, Switzerland) · 2022Review
- Bioactive Peptides against Human Apicomplexan Parasites.Antibiotics (Basel, Switzerland) · 2022Review
- New Halogenated Compounds fromMolecules (Basel, Switzerland) · 2022Article
- Cyanobacterial secondary metabolites towards improved commercial significance through multiomics approaches.World journal of microbiology & biotechnology · 2022Review
- Pipecolisporin, a Novel Cyclic Peptide with Antimalarial and Antitrypanosome Activities from a Wheat EndophyticPharmaceuticals (Basel, Switzerland) · 2021Article
- Potentials of marine natural products against malaria, leishmaniasis, and trypanosomiasis parasites: a review of recent articles.Infectious diseases of poverty · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
A new cyclic peptide, kakeromamide B (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.